By Katherine Hamilton
Omeros shares gained Thursday after the company shared positive results for a trial of its treatment of a stem-cell transplantation complication.
The stock rose 52% to $11.15. It has nearly doubled over the past month and a half after reporting third-quarter earnings in mid-November.
The Seattle-based biopharmaceutical company said its narsoplimab treatment met its primary endpoint in a trial.
Narsoplimab is a monoclonal antibody designed to treat a complication in stem-cell transplantation called hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).
The trial compared the survival rate of 28 patients with more than 100 patients in a control group who did not receive narsoplimab. Patients receiving the treatment showed significantly better survival rates.
Omeros plans to resubmit a biologics license application for its narsoplimab to the Food and Drug Administration as soon as possible, it said. If approved, narsoplimab would be the first approved treatment for TA-TMA, Omeros said.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
December 19, 2024 10:56 ET (15:56 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。